Alexion Pharmaceuticals (ALXN) : 18 analysts are covering Alexion Pharmaceuticals (ALXN) and their average rating on the stock is 1.47, which is read as a Strong Buy. 13 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Alexion Pharmaceuticals (ALXN) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Alexion Pharmaceuticals (ALXN) has been rated by 15 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $221 and the lowest price target forecast is $145. The average forecast of all the analysts is $193.47 and the expected standard deviation is $24.47.
Alexion Pharmaceuticals (NASDAQ:ALXN): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $117.27 and $116.40 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $121.63. The buying momentum continued till the end and the stock did not give up its gains. It closed at $121.12, notching a gain of 2.96% for the day. The total traded volume was 2,723,458 . The stock had closed at $117.64 on the previous day.
Also, Brokerage firm Citigroup upgrades its rating on Alexion Pharmaceuticals (NASDAQ:ALXN). As per the latest information, the brokerage house maintains the price target to $154 per share from a prior target of $154. The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by the firm was issued on June 27, 2016. The company shares have dropped -36.29% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $208.88 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $134.36 and the 200 Day Moving Average price is recorded at $146.56.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. As of June 23, 2015, the Company had eight product candidates in clinical trials for 11 indications. The Companys product pipeline includes complement inhibitor portfolio, metabolic rare disease portfolio and preclinical candidates. Its complement inhibitor portfolio includes Soliris, ALXN1007, ALXN1210 and ALXN5500. Its metabolic rare disease portfolio includes Strensiq, Kanuma, ALXN1101 and SBC-103. The Companys preclinical candidates include mRNA Therapies, SBC-105 and other complement inhibitors. Its Soliris is approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening ultra-rare disorders.